Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a confirmed diagnosis of hepatocellular carcinoma (liver cancer) that cannot be treated with curative intent.
• People whose liver cancer has shown clear signs of growing or spreading during or after at least one prior treatment, or who were unable to tolerate prior treatment — as long as that prior treatment did not include cabozantinib.
• People who have received no more than two prior treatment courses for advanced or metastatic liver cancer (not counting cabozantinib; palliative radiation or local treatments to the liver do not count as a prior line of therapy).
• People whose liver function falls into Child-Pugh class A, or Child-Pugh class B with a score of B7 or B8 (a measure of liver disease severity — confirm with trial site).
• People whose cancer can be measured on scans according to standard criteria called RECIST v1.1 (confirm with trial site).
• People aged 18 years or older.
• People who are reasonably active and able to care for themselves, as measured by a standard performance scale (ECOG 0–1, or Karnofsky score of 60% or above — confirm with trial site).
• People whose blood counts, liver function, kidney function, and other organ measurements meet the specific levels required by the trial (the trial site will check these through blood tests).
• People who are able to swallow tablets or liquid medication, or receive it through a feeding tube if needed.
• People who are able to understand the study, agree to its requirements, and sign a consent form.
• People of childbearing potential, and those with sperm-producing reproductive capacity, who agree to use highly effective contraception during the study and for a specified period after the last dose of treatment (the trial site will provide details).

Who may not be able to join:

• People who have previously been treated with the study drug, zanzalintinib.
• People who have previously been treated with cabozantinib.
• People who have received three or more prior treatment courses for advanced liver cancer.
• People who have taken any small-molecule targeted therapy (including investigational drugs of that type) within 14 days before the study start date.
• People who have received chemotherapy, immunotherapy, radiation, or other systemic cancer treatments within 4 weeks before the study start date.
• People who have had radiation therapy to bone metastases within 14 days, or any other radiation within 4 weeks, before the study start date.
• People who have received radioactive substance-based treatments within 6 weeks before the study start date.
• People who have had local liver treatments — such as surgery, ablation, or chemoembolisation — within 28 days before the study start date.
• People who still have unresolved side effects from previous cancer treatment that are grade 2 or higher in severity (except for certain conditions such as hair loss, which may be allowed — confirm with trial site).
• People with another active cancer that has been progressing or required treatment within the past 2 years (some early-stage or fully treated skin cancers and certain other low-risk cancers may be exceptions — confirm with trial site).
• People with brain metastases (cancer spread to the brain) that have not been adequately treated and stable for at least 28 days before the study start date (some small, stable, untreated lesions may be considered — confirm with trial site).
• People with a known history of serious allergic reactions to drugs with a similar chemical makeup to zanzalintinib.
• People taking certain blood-thinning or antiplatelet medications (such as warfarin or clopidogrel); some specific anticoagulants at low or stable doses may be permitted — confirm with trial site.
• People taking herbal supplements or traditional medicines to treat their cancer within 2 weeks before the study start date (taking these for symptom relief only may be allowed — confirm with trial site).
• People with serious uncontrolled illness or other significant medical conditions that the trial team considers unsafe.
• People who have had significant bleeding episodes (such as coughing or vomiting blood, or other major bleeding) within the 12 weeks before joining the trial.
• People with certain lung lesions causing symptoms, or cancer growing into major blood vessels such as the main lung artery or the aorta (some exceptions may apply — confirm with trial site).
• People who have had major surgery within 8 weeks, keyhole (laparoscopic) surgery within 28 days, or minor surgery within 5 days before the study start date, or whose surgical wounds have not fully healed.
• People with a heart rhythm measurement called the QTcF interval above 480 ms on a recent ECG (heart tracing) taken within 14 days before the study start date.
• People who are pregnant or breastfeeding, as the study drug may be harmful to an unborn baby or infant.
• People whose mental health, social circumstances, or other conditions would make it difficult to safely follow the study requirements or give informed consent, in the opinion of the treating doctor.
• People who have had hepatic encephalopathy (confusion caused by liver failure) within 6 weeks before the study start date.
• People with significant fluid build-up in the abdomen (ascites) that has required drainage or increased medication within 2 weeks before the study start date.

Important: Always verify eligibility with the trial site directly before applying.